Psoriasis

Weekend treatment with cyclosporine may be beneficial for patients with moderate to severe psoriasis, according to a new study.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

This research indicates that psychological well-being serves a key role in the management of psoriatic disease.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

Based on these findings, Innovent plans to submit a New Drug Application to the Center for Drug Evaluation of National Medical Product Administration.

Researchers from NYU Langone recently published a study clarifying the role of HIF-1-alpha in inflammation and psoriasis, which has been unclear until now.

A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.

Ayesha Patrick, the founder of Sistas With Psoriasis, spoke with Dermatology Times about her involvement in AbbVie's Clearly Me campaign.

Clearly Me uses portraiture to spotlight the journeys of psoriasis patients Katie Lowes, DaQuane Cherry, Ayesha Patrick, and Joanna “JoJo” Pomerantz.

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.

Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.

A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.

A cross-sectional study revealed an increase and heightened prevalence of Demodex and demodicosis in individuals with psoriasis receiving biologic therapy.

At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.

Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.

A recent review and meta-analysis says this statistic may be due in part to nocebo effects.

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

Versus placebo, topical melatonin and rosuvastatin reduced psoriatic plaque severity with a favorable safety profile.

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.